Idebenone - Santhera Pharmaceuticals

Drug Profile

Idebenone - Santhera Pharmaceuticals

Alternative Names: Catena; Raxone; SNT-MC17; Sovrima

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Santhera Pharmaceuticals
  • Developer Columbia University; National Institute of Neurological Disorders and Stroke; Santhera Pharmaceuticals; Takeda
  • Class Benzoquinones; Coenzymes; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Antioxidants; Electron transport chain complex protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia; Leber's hereditary optic atrophy; Duchenne muscular dystrophy
  • New Molecular Entity No
  • Available For Licensing Yes - Duchenne muscular dystrophy

Highest Development Phases

  • Marketed Leber's hereditary optic atrophy
  • Preregistration Duchenne muscular dystrophy
  • Phase II Multiple sclerosis
  • Suspended Friedreich's ataxia
  • No development reported MELAS syndrome

Most Recent Events

  • 23 Dec 2016 UK's Medicines and Healthcare Products Regulatory Agency (MHRA) designates idebenone as Promising Innovative Medicine (PIM) for Duchenne muscular dystrophy
  • 08 Nov 2016 The Swiss Agency for Therapeutic Products (Swissmedic) accepts MAA for idebenone for Duchenne muscular dystrophy for review
  • 01 Nov 2016 Santhera completes a phase I drug-drug interaction trial in France (NCT02887443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top